1-(6-(5-(2,6-difluorophenyl)-1H-indazol-3-yl)pyrazin-2-yl)piperidin-3-amine | 1380911-90-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 1-(6-(5-(2,6-difluorophenyl)-1H-indazol-3-yl)pyrazin-2-yl)piperidin-3-amine
• 英文别名: 1-[6-[5-(2,6-difluorophenyl)-1H-indazol-3-yl]pyrazin-2-yl]piperidin-3-amine
• CAS: 1380911-90-9
• 化学式: C₂₂H₂₀F₂N₆
• 分子量: 406.438
• InChiKey: HWIDISMNBLRQNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  83.7
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  t-butyl piperidin-3-ylcarbamate 在 盐酸 、 copper(l) iodide 、 四(三苯基膦)钯 、 potassium carbonate 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 生成 1-(6-(5-(2,6-difluorophenyl)-1H-indazol-3-yl)pyrazin-2-yl)piperidin-3-amine
  参考文献：
  名称：

  The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors

  摘要：

  The three Pim kinases are a small family of serine/threonine kinases regulating several signaling pathways that are fundamental to tumorigenesis. As such, the Pim kinases are a very attractive target for pharmacological inhibition in cancer therapy. Herein, we describe our efforts toward the development of a potent, pan-Pim inhibitor. The synthesis and hit-to-lead SAR development from a 3-(pyrazin-2-yl)-1H-indazole derived hit 2 to the identification of a series of potent, pan-Pim inhibitors such as 13o are described. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2014.12.068

文献信息

• BICYCLIC COMPOUNDS AS PIM INHIBITORS
  申请人：Wang Hui-Ling

  公开号：US20140031360A1

  公开（公告）日：2014-01-30

  The invention relates to bicyclic compounds of formula (1′), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  本发明涉及公式（1'）的双环化合物及其盐。在某些实施例中，本发明涉及Pim-1和/或Pim-2和/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，本发明涉及包含所披露化合物的制药组合物及其在预防和治疗Pim激酶相关疾病和病症，尤其是癌症方面的应用。
• Bicyclic compounds as Pim inhibitors
  申请人：Wang Hui-Ling

  公开号：US09090593B2

  公开（公告）日：2015-07-28

  The invention relates to bicyclic compounds of formula (1′), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  该发明涉及公式（1'）的双环化合物及其盐。在某些实施例中，该发明涉及Pim-1和/或Pim-2和/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，该发明涉及含有此处披露的化合物的制药组合物及其在预防和治疗Pim激酶相关疾病和病症，尤其是癌症方面的用途。
• [EN] BICYCLIC COMPOUNDS AS PIM INHIBITORS<br/>[FR] COMPOSÉS BICYCLIQUES EN TANT QU'INHIBITEURS DE PIM
  申请人：AMGEN INC

  公开号：WO2012078777A1

  公开（公告）日：2012-06-14

  The invention relates to bicyclic compounds of formula (1'), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  本发明涉及公式（1'）的双环化合物及其盐。在某些实施例中，本发明涉及Pim-1和/或Pim-2以及/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，本发明涉及包含所述化合物的制药组合物以及它们在预防和治疗与Pim激酶相关的疾病和病症，尤其是癌症方面的应用。
• US9090593B2
  申请人：——

  公开号：US9090593B2

  公开（公告）日：2015-07-28
• The discovery of novel 3-(pyrazin-2-yl)-1H-indazoles as potent pan-Pim kinase inhibitors
  作者：Hui-Ling Wang、Victor J. Cee、Frank Chavez、Brian A. Lanman、Anthony B. Reed、Bin Wu、Nadia Guerrero、J. Russell Lipford、Christine Sastri、Jeff Winston、Kristin L. Andrews、Xin Huang、Matthew R. Lee、Christopher Mohr、Yang Xu、Yihong Zhou、Andrew S. Tasker

  DOI：10.1016/j.bmcl.2014.12.068

  日期：2015.2

  The three Pim kinases are a small family of serine/threonine kinases regulating several signaling pathways that are fundamental to tumorigenesis. As such, the Pim kinases are a very attractive target for pharmacological inhibition in cancer therapy. Herein, we describe our efforts toward the development of a potent, pan-Pim inhibitor. The synthesis and hit-to-lead SAR development from a 3-(pyrazin-2-yl)-1H-indazole derived hit 2 to the identification of a series of potent, pan-Pim inhibitors such as 13o are described. Published by Elsevier Ltd.